| Jeffrey J Gerstner, RPH | |
|
4061 Indian Creek Parkway, Suite 120, Overland Park, KS 66207-4030 | |
| (913) 323-4777 | |
| (913) 323-4778 |
| Full Name | Jeffrey J Gerstner |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 4061 Indian Creek Parkway, Overland Park, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780979518 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 1-11428 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey J Gerstner, RPH 4061 Indian Creek Parkway, Suite 120, Overland Park, KS 66207-4030 Ph: (913) 323-4777 | Jeffrey J Gerstner, RPH 4061 Indian Creek Parkway, Suite 120, Overland Park, KS 66207-4030 Ph: (913) 323-4777 |
News Archive
Using the bells and whistles of a state-of-the-art entertainment arcade, a University at Buffalo Graduate School of Education project aims to improve the driving habits of teenagers at the very top of the risk pool, and at the same time bring child and parent together for a happier, better functioning family.
In light of a paper released by the Office of the Chief Scientist today, NPS MedicineWise is calling on every Australian to do their part in the fight against antibiotic resistance in our community.
The most important factor in what kind of sweetener people prefer has little to do with how sweet it tastes. Rather, it has more to do with other tastes in the sweetener, such as bitterness or sourness, new research suggests.
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, has signed a 10-year lease agreement for a new 46,000-square-foot manufacturing facility in Pearland, Texas.
› Verified 3 days ago
Jennifer Ortolani, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9000 Metcalf Ave, Overland Park, KS 66212 Phone: 613-649-4314 Fax: 913-649-4483 | |
Monique Hsu, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7000 W 75th St, Overland Park, KS 66204 Phone: 913-432-3396 | |
Elisabeth Gossman, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9501 Nall Ave, Overland Park, KS 66207 Phone: 913-648-1210 | |
Barbara C Loehr, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8901 W 75th St, Overland Park, KS 66204 Phone: 913-789-3976 | |
Dr. Barbara Hilmes Bodanske, RPH PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 13811 Woodward St, Overland Park, KS 66223 Phone: 913-681-5425 | |
Katelyn Steele, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7000 W 75th St, Overland Park, KS 66204 Phone: 913-432-3396 | |
Dr. Michael Porterfield, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 12290 College Blvd, Overland Park, KS 66210 Phone: 913-327-1332 Fax: 913-327-7533 |